Stock 002755 BEIJING AOSAIKANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Beijing Aosaikang Pharmaceutical Co., Ltd. Stock

Equities

002755

CNE100001X92

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
11.45 CNY -0.26% Intraday chart for Beijing Aosaikang Pharmaceutical Co., Ltd. +2.42% +5.82%
Apr. 28 Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 05 Beijing Aosaikang Pharma's Unit Gets Nod to Market Delafloxacin for Injection MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 1.87B 259M Sales 2023 1.44B 200M Capitalization 10.04B 1.39B
Net income 2022 -226M -31.28M Net income 2023 -149M -20.62M EV / Sales 2022 3.11 x
Net cash position 2022 1.55B 215M Net cash position 2023 1.64B 227M EV / Sales 2023 5.82 x
P/E ratio 2022
-33.1 x
P/E ratio 2023
-67.6 x
Employees 1,215
Yield 2022 *
-
Yield 2023
-
Free-Float 18.22%
More Fundamentals * Assessed data

Chart Beijing Aosaikang Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Beijing Aosaikang Pharmaceutical Co., Ltd.

Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Aosaikang Pharma's Unit Gets Nod to Market Delafloxacin for Injection MT
Aosaikang Pharmaceutical Registers Breast Cancer Drug MT
Aosaikang Pharmaceutical's Unit Gets Nod for Two Drugs MT
Aosaikang Pharmaceutical's Unit Gets Nod to Trial ASKC202 Tablets MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Aosaikang Pharmaceutical's Unit Gets Nod to Test Gastric Cancer Drug MT
Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) added to S&P Global BMI Index CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Aosaikang Pharma's Unit Gets Nod to Amend Instructions for Heart Drug MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aosaikang Pharma Unit Registers Acid Reflux Drug in China MT
Aosaikang Pharma Registers Three Drugs MT
Aosaikang Pharma US Unit Gets Regulatory Nod For Anti-Tumor Drug Trial MT
More news

Press releases Beijing Aosaikang Pharmaceutical Co., Ltd.

Shield Therapeutics : Preliminary Results for the Year Ended 31 December 2019 AQ
Shield Therapeutics : AEGIS-H2H study update AQ
Shield Therapeutics : announces exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd in China AQ
More press releases

Quotes and Performance

1 day-0.26%
1 week+2.42%
Current month+2.42%
1 month+13.93%
3 months+53.07%
6 months+10.20%
Current year+5.82%
More quotes

Highs and lows

1 week
10.81
Extreme 10.81
11.71
1 month
8.33
Extreme 8.33
11.71
Current year
6.50
Extreme 6.5
11.71
1 year
6.50
Extreme 6.5
12.28
3 years
6.50
Extreme 6.5
14.28
5 years
6.50
Extreme 6.5
22.28
10 years
6.50
Extreme 6.5
22.28
More quotes

Managers and Directors - Beijing Aosaikang Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Jing Fei Ma CEO
 Chief Executive Officer 36 19-09-29
Tao Han DFI
 Director of Finance/CFO 42 19-02-17
You Yin Xu BRD
 Director/Board Member 56 19-02-17
Members of the board TitleAgeSince
Jian Wen Liu BRD
 Director/Board Member 65 19-02-17
Qing Chen CHM
 Chairman 65 19-02-17
You Yin Xu BRD
 Director/Board Member 56 19-02-17
More insiders

ETFs positioned on Beijing Aosaikang Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 0 M€ +3.45% -
More ETFs positioned on Beijing Aosaikang Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
24-05-08 11.45 -0.26% 5,992,160
24-05-07 11.48 +1.41% 9,519,370
24-05-06 11.32 +1.25% 10,835,720
24-04-30 11.18 +3.71% 14,053,150

End-of-day quote Shenzhen S.E., May 07, 2024

More quotes

Company Profile

BEIJING AOSAIKANG PHARMACEUTICAL CO., LTD., formerly Beijing New Oriental Star Petrochemical Engineering Co., Ltd., is a China-based company mainly engaged in pharmaceutical manufacturing business. The Company produces proton pump inhibitor injections through its subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Sector
Pharmaceuticals
Calendar
2024-05-29 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BEIJING AOSAIKANG PHARMACEUTICAL CO., LTD. Stock Beijing Aosaikang Pharmaceutical Co., Ltd.
+5.82% 1.47B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.95% 698B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.97% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.83% 328B
ABBVIE INC. Stock AbbVie Inc.
+3.54% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.02% 238B
NOVARTIS AG Stock Novartis AG
+6.68% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 198B
AMGEN INC. Stock Amgen Inc.
+6.70% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002755 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW